Why invest in us ?

Our live-cell platform for discovering human therapeutic antibodies against GPCRs holds great potentials as it will likely facilitate the advent of a new class of antibody drugs targeting at a large family of proteins known for their important roles in a wide range of cellular processes.   These antibody drugs may offer novel solutions to many diseases some of which still lack effective medical interventions at present.  We believe that this live-cell system is by far better suited for discovery of functional antibodies against GPCRs than any other in vitro systems currently available.

For information on investment and/or collaboration contact us